In patients with heart failure, SGLT2 inhibitors after TAVI are associated with major risk reductions in a clinical trial ...

SGLT2 inhibitor use was not associated with an increased risk for postoperative diabetic ketoacidosis among patients with type 2 diabetes.

In a recent study involving nearly 400,000 adults over the age of 50 with type 2 diabetes, researchers found that two classes ...

“CareMed is grateful for the opportunity to become a specialty pharmacy provider for Vanrafia ™ ,” said Benito Fernandez. “We are proud to add Vanrafia ™ for the treatment of primary immunoglobulin A ...

Dozens of trials testing GLP-1 drugs like semaglutide, the medicine in Ozempic and Wegovy, against a placebo suggest that ...

It’s possible that they may play a role as a preventative measure in the future,” said Dr. Catriona Reddin told The Post.

FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...

FAT jabs may lower the risk of the UK’s biggest killer, according to a study of almost 400,000 adults with type 2 diabetes. The research, published in JAMA Neurology, examined two types of ...

The following is a summary of “Optimizing SGLT2 inhibitor and GLP-1 RA prescribing in high-risk patients with diabetes: a ...

SGLT2 inhibitors vs placebo were associated with reduced heart failure hospitalization among patients with history of myocardial infarction.

Two new studies published in JAMA Neurology reveal that GLP-1 receptor agonists, like Ozempic and Trulicity, may ...